The Role of Immunosuppression in Malignancies Among 351 Pediatric Renal Transplant Patients

L. Berardinelli, M. Raiteri, L. Ghio, P. G. Messa, G. Montagnino

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The incidence of de novo malignancies over a 38 year experience in 351 children ranging in age from 2 to 18 years was investigated among subjects prescribed various immunosuppressive protocols. There were 14 children (3.98%) who showed de novo malignancies, namely, 4.86 cancers for every 1000 graft-function years (GFYs). Among patients who had grafts functioning for >10 years, 7.4% suffered from cancer. Nine patients survive without a recurrence at a mean of 12.5 ± 6.6 years including 6 with graft function. Among group I who were treated with pre-calcineurin inhibitor (CNI) therapy 3 (3.8%) children (1 male and 2 females) developed a malignancy at a mean of 15.2 ± 11.9 years posttransplant (range, 7-35), for 4.65 cancers every 1000 GFYs. Two of them survive with functioning grafts. Among group II, who were treated by CNIs there were 273 children including 24 retransplants. Group II showed 11 malignancies (4.0%), for 5.04 malignancies for every 1000 GFYs. The incidence of cancer was similar in the 2 groups, undergoing different immunosuppressive regimens; however, the malignancies in the CNI- group were more precocious, compared with those of the conventionally-treated cohort.

Original languageEnglish
Pages (from-to)1166-1168
Number of pages3
JournalTransplantation Proceedings
Volume42
Issue number4
DOIs
Publication statusPublished - May 2010

Fingerprint

Immunosuppression
Pediatrics
Transplants
Kidney
Neoplasms
Immunosuppressive Agents
Incidence
Recurrence

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

The Role of Immunosuppression in Malignancies Among 351 Pediatric Renal Transplant Patients. / Berardinelli, L.; Raiteri, M.; Ghio, L.; Messa, P. G.; Montagnino, G.

In: Transplantation Proceedings, Vol. 42, No. 4, 05.2010, p. 1166-1168.

Research output: Contribution to journalArticle

@article{03adee7cd37a4abaac97e0d587d10ce0,
title = "The Role of Immunosuppression in Malignancies Among 351 Pediatric Renal Transplant Patients",
abstract = "The incidence of de novo malignancies over a 38 year experience in 351 children ranging in age from 2 to 18 years was investigated among subjects prescribed various immunosuppressive protocols. There were 14 children (3.98{\%}) who showed de novo malignancies, namely, 4.86 cancers for every 1000 graft-function years (GFYs). Among patients who had grafts functioning for >10 years, 7.4{\%} suffered from cancer. Nine patients survive without a recurrence at a mean of 12.5 ± 6.6 years including 6 with graft function. Among group I who were treated with pre-calcineurin inhibitor (CNI) therapy 3 (3.8{\%}) children (1 male and 2 females) developed a malignancy at a mean of 15.2 ± 11.9 years posttransplant (range, 7-35), for 4.65 cancers every 1000 GFYs. Two of them survive with functioning grafts. Among group II, who were treated by CNIs there were 273 children including 24 retransplants. Group II showed 11 malignancies (4.0{\%}), for 5.04 malignancies for every 1000 GFYs. The incidence of cancer was similar in the 2 groups, undergoing different immunosuppressive regimens; however, the malignancies in the CNI- group were more precocious, compared with those of the conventionally-treated cohort.",
author = "L. Berardinelli and M. Raiteri and L. Ghio and Messa, {P. G.} and G. Montagnino",
year = "2010",
month = "5",
doi = "10.1016/j.transproceed.2010.03.131",
language = "English",
volume = "42",
pages = "1166--1168",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - The Role of Immunosuppression in Malignancies Among 351 Pediatric Renal Transplant Patients

AU - Berardinelli, L.

AU - Raiteri, M.

AU - Ghio, L.

AU - Messa, P. G.

AU - Montagnino, G.

PY - 2010/5

Y1 - 2010/5

N2 - The incidence of de novo malignancies over a 38 year experience in 351 children ranging in age from 2 to 18 years was investigated among subjects prescribed various immunosuppressive protocols. There were 14 children (3.98%) who showed de novo malignancies, namely, 4.86 cancers for every 1000 graft-function years (GFYs). Among patients who had grafts functioning for >10 years, 7.4% suffered from cancer. Nine patients survive without a recurrence at a mean of 12.5 ± 6.6 years including 6 with graft function. Among group I who were treated with pre-calcineurin inhibitor (CNI) therapy 3 (3.8%) children (1 male and 2 females) developed a malignancy at a mean of 15.2 ± 11.9 years posttransplant (range, 7-35), for 4.65 cancers every 1000 GFYs. Two of them survive with functioning grafts. Among group II, who were treated by CNIs there were 273 children including 24 retransplants. Group II showed 11 malignancies (4.0%), for 5.04 malignancies for every 1000 GFYs. The incidence of cancer was similar in the 2 groups, undergoing different immunosuppressive regimens; however, the malignancies in the CNI- group were more precocious, compared with those of the conventionally-treated cohort.

AB - The incidence of de novo malignancies over a 38 year experience in 351 children ranging in age from 2 to 18 years was investigated among subjects prescribed various immunosuppressive protocols. There were 14 children (3.98%) who showed de novo malignancies, namely, 4.86 cancers for every 1000 graft-function years (GFYs). Among patients who had grafts functioning for >10 years, 7.4% suffered from cancer. Nine patients survive without a recurrence at a mean of 12.5 ± 6.6 years including 6 with graft function. Among group I who were treated with pre-calcineurin inhibitor (CNI) therapy 3 (3.8%) children (1 male and 2 females) developed a malignancy at a mean of 15.2 ± 11.9 years posttransplant (range, 7-35), for 4.65 cancers every 1000 GFYs. Two of them survive with functioning grafts. Among group II, who were treated by CNIs there were 273 children including 24 retransplants. Group II showed 11 malignancies (4.0%), for 5.04 malignancies for every 1000 GFYs. The incidence of cancer was similar in the 2 groups, undergoing different immunosuppressive regimens; however, the malignancies in the CNI- group were more precocious, compared with those of the conventionally-treated cohort.

UR - http://www.scopus.com/inward/record.url?scp=77952571583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952571583&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2010.03.131

DO - 10.1016/j.transproceed.2010.03.131

M3 - Article

C2 - 20534251

AN - SCOPUS:77952571583

VL - 42

SP - 1166

EP - 1168

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -